Small cap₹1,927 cr₹1.0 cr traded a dayThin: a ₹2 lakh order is 2.0% of a normal day
Close on 11 September 2026
2,264.90
−0.62%
52-week range78% of the way up
1,259.102,545.00
Market cap
1,927 cr
P/E (TTM)
14.1×
EPS (TTM)
160.95
Revenue YoY
-8.2%
Q1 FY27
Profit YoY
+459.3%
Net margin
125.2%
+104.7pt vs a year ago
Growth trend
-30.4pt
vs last quarter’s YoY
1 month
-8.0%
Below 52w high
11.0%
RSI (14)
43
Daily swing
4.3%
average true range
Volume
0.6×
vs 20-day average
Traded
₹1 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Above the median
+24.2%
One-year return
Above the median
+14.5%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
-8.2%
Below the 52-week high
distance from the highest close of the year
11.0%
How it has performed
price return over each window, beside the median NSE stock over the same days
The read
written from the numbers on this page
More of the measured facts point up than down6 supporting, 1 against, 1 worth knowing
Supporting
trading 24% above its 200-day average
up 14% over twelve months
matches beating the market for 6 months, which has beaten the market by +0.50 points over 20 sessions across 60,366 past signals
2 of the scans it matches have a positive measured record
3 independent kinds of evidence agree today, which is uncommon
net margin has widened from 20.2% to 125.2% across four quarters
Against
revenue fell 8% year on year in the quarter ending 30 June 2026
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
The market itself is rangebound tonight. Each scan's record is measured separately for this regime; the figure beside each chip above is the one that applies, not the all-weather number.
What would change these counts: the close crossing its 200-day average, which is 1,824 tonight and moves every session.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working5
Hester Biosciences net profit rose 459.3% year on year, from Rs 17 cr to Rs 97 cr.
+459.3%Rs 17 crRs 97 cr
Hester Biosciences profit grew +459.3% while revenue fell -8.2%.
+459.3%-8.2%
Hester Biosciences' net margin moved from 20.6% to 125.2%.
20.6%125.2%
Trading 24.2% above its 200-day simple average, which is the line most investors use to separate a bull phase from a bear one.
+24.2%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching2
Revenue -8.2% year on year, Rs 84 cr to Rs 77 cr.
-8.2%Rs 84 crRs 77 cr
Only ₹1.0 crore changes hands on a median day. A large order moves this price by itself.
₹1.0 cr
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
What the scans say today
5 of 57 matched on 11 Sep
HESTERBIO matches 5 of the 57 scans today, across 3 different kinds of evidence (not counting 2 that match most of the market tonight). Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses. It is in none of the 19 published portfolios on the arena tonight.
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
profit rose 459% year on year
net margin widened from 16.5% to 125.2%
Going against it
revenue fell 8% against the same quarter a year earlier
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
77
100
97
113.71
125.2%
Q4 FY26
31 Mar · consolidated
100
23
17
19.45
16.5%
Q3 FY26
31 Dec · consolidated
77
12
9
10.94
12.0%
Q2 FY26
30 Sep · consolidated
71
15
14
16.85
20.2%
Q1 FY26
30 Jun · consolidated
84
19
17
20.33
20.6%
Q4 FY25
31 Mar · consolidated
82
2
2
1.82
1.9%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Valuation against its own history
500 sessions since 27 September 2024
15×
median 37×
86×
now 14×
HESTERBIO trades at 14× trailing earnings, below its median of 37× over this window — 62% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
How it is priced against the universe
tonight’s multiples, ranked against every company we scan
Measure
Tonight
Where it ranks
Price to earnings
trailing four quarters of profit
14.1×
cheaper than 79% of scanned companies
Price to sales
trailing four quarters of revenue
5.92×
cheaper than 21% of scanned companies
Earnings yield
7.1%
profit as a share of the market value — the P/E upside down
P/E to growth
0.03
the multiple divided by the year-on-year profit growth rate
Value composite
50
average percentile across the three multiples; 0 is the cheapest company scanned, 100 the dearest
Quality checklist
five of Piotroski’s nine tests, the ones Indian filings support
2 of 5
✓ profitable over four quarters✗ cash conversion above 100%✗ borrowings under half of equity✓ margin up on a year ago✗ revenue up on a year ago
A low multiple is a statement about expectations, not about quality: the market usually expects less from a cheap company, and is often right. These are rankings, not fair values.
Credit rating filings were typically +0.38pt vs the market over the next 5 sessions (n=422)
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-4.6%
Versus 200-day average+24.2%
Below 52-week high11.0%
Above 52-week low+79.9%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)42.9
Higher closes in last 51 of 5
Six-month return+59.17%
Risk and liquidity
What a position costs to hold and to exit. Delivery is the share of the day’s volume taken into demat rather than squared off; trade size says whether the day’s tickets were large or small.
Typical daily swing (ATR)4.29%
What ₹1 lakh here moves on a normal dayabout ₹4,294